Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEHAWNYSE:AMPENASDAQ:CALANASDAQ:EGLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEHAWAesther Healthcare Acquisition$0.01$0.01$0.06▼$0.33N/AN/A34,287 shs30,000 shsAMPEAmpio Pharmaceuticals$0.02$0.00▼$0.45N/A4.76600 shs46 shsCALACalithera Biosciences$0.00$0.00▼$0.05N/A-2.8213,914 shs5 shsEGLTEgalet$0.01$0.24$0.03▼$1.57N/AN/A853,425 shsN/AThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEHAWAesther Healthcare Acquisition0.00%-8.70%+30.43%-61.64%-80.94%AMPEAmpio Pharmaceuticals0.00%-96.30%-96.67%-83.33%-99.90%CALACalithera Biosciences0.00%0.00%-95.00%-83.33%-99.00%EGLTEgalet0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AAMPEAmpio Pharmaceuticals0.0592 of 5 stars0.03.00.00.00.00.00.0CALACalithera Biosciences0.6441 of 5 stars0.01.00.04.50.60.00.0EGLTEgaletN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEHAWAesther Healthcare Acquisition 0.00N/AN/AN/AAMPEAmpio Pharmaceuticals 0.00N/AN/AN/ACALACalithera Biosciences 0.00N/AN/AN/AEGLTEgalet 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AAMPEAmpio PharmaceuticalsN/AN/AN/AN/A$4.04 per shareN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AN/AEGLTEgaletN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEHAWAesther Healthcare AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AAMPEAmpio Pharmaceuticals-$8.63M-$11.01N/AN/AN/AN/AN/AN/AN/ACALACalithera Biosciences-$39.65MN/A0.00N/AN/AN/AN/AN/AN/AEGLTEgaletN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AEGLTEgaletN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEHAWAesther Healthcare AcquisitionN/AAMPEAmpio Pharmaceuticals5.73%CALACalithera BiosciencesN/AEGLTEgalet19.20%Insider OwnershipCompanyInsider OwnershipAEHAWAesther Healthcare AcquisitionN/AAMPEAmpio Pharmaceuticals3.30%CALACalithera Biosciences6.60%EGLTEgalet2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEHAWAesther Healthcare Acquisition2N/AN/ANot OptionableAMPEAmpio Pharmaceuticals201.14 million1.10 millionNo DataCALACalithera Biosciences604.87 million4.55 millionNot OptionableEGLTEgaletN/AN/AN/AOptionableEGLT, AEHAW, AMPE, and CALA HeadlinesRecent News About These CompaniesAgenda released for SMi Group’s Controlled Release Delivery 2018September 30, 2024 | pharmaphorum.comPMark J. Alberts, MDMay 18, 2024 | medscape.comMProvenance du réseau au premier degré de Niels AckermannDecember 29, 2023 | zonebourse.comZRobert RadieDecember 29, 2023 | zonebourse.comZOpioids Agonist Drugs Market Is Expected To Expand At A ... - Digital JournalMay 9, 2023 | news.google.comNGlobal Opioids Agonist Drugs Market Size Throw Innovation-Based ... - Cottonwood Holladay JournalMay 9, 2023 | news.google.comNPain Therapeutics Market Research Report 2023-2031 Market R ... - The Northwestern ExaminerMay 7, 2023 | news.google.comNPostoperative Pain Management Market Growth, Region Analysis ... - Digital JournalApril 21, 2023 | news.google.comNThis Day in DePauw HistoryApril 17, 2023 | depauw.eduDNasal Spray Market Share, Industry Growth, Trend, Drivers ... - Digital JournalApril 11, 2023 | news.google.comNOpioids Agonist Drugs Market Overall Study Report 2023-2030 ... - Digital JournalApril 7, 2023 | news.google.comNDemerol (Meperidine) Market Size, Share, Growth Report 2030 - openPRApril 5, 2023 | news.google.comNGlobal Opioids Market to Reach $31.7 Billion by 2030 - GlobeNewswireMarch 30, 2023 | news.google.comNOpioids Market Latest Advancements and Business Opportunities ... - Digital JournalMarch 15, 2023 | news.google.comNMusculoskeletal Pain Emerging Pipeline and Marketed Drugs Assessment | Clinical Trials, Latest FDA, EMA, and P - openPRMarch 9, 2023 | news.google.comN[PDF] Opioids Market market Research Report: Size, Share ... - Digital JournalMarch 9, 2023 | news.google.comNEndorphins Market Size, Share, Growth Statistics, Top Key Players ... - Digital JournalMarch 6, 2023 | news.google.comNRising Trends of Demerol (Meperidine) Market will Witness Substantial Growth With in-detailed Competitor Analy - openPRFebruary 23, 2023 | news.google.comNOpioids Agonist Drugs Market Is Thriving Worldwide-Purdue ... - Trending in PakistanFebruary 21, 2023 | news.google.comNNasal Spray Market Status, Trends and Key Players Analysis ... - Digital JournalFebruary 17, 2023 | news.google.comNNew MarketBeat Followers Over TimeEGLT, AEHAW, AMPE, and CALA Company DescriptionsAesther Healthcare Acquisition NASDAQ:AEHAW$0.0091 0.00 (0.00%) As of 07/3/2025Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.Ampio Pharmaceuticals NYSE:AMPEAmpio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.Calithera Biosciences NASDAQ:CALACalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Egalet NASDAQ:EGLTEgalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate; and ARYMO ER, an extended-release (ER) morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The company is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER. In addition, its other products include Egalet-003, an AD stimulant product candidate; and Egalet-004, an AD, ER hydrocodone-based product candidate. The company has a collaboration and license agreement with Acura Pharmaceuticals, Inc. to commercialize OXAYDO tablets; and Septodont, Inc. to promote SPRIX Nasal Spray. Egalet Corporation was founded in 2010 and is headquartered in Wayne, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
